CrystecPharma, a pharmaceutical crystal and particle engineering company, has opened a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., along with a research facility, located at Haimen Science and Technology Park in Haimen City, Jiangsu Province, China.

Crystec’s new R&D center has been established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform jointly funded by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the Haimen government. The platform, which has received ￡550 m equivalent in investment, is dedicated to accelerating pharmaceutical product innovation underpinned by advanced pharmaceutical excipients and drug delivery technologies. Crystec’s mSAS technology will play a key role in enabling the development of new therapeutics, creation of value-added medicines, and in simplification of formulations and manufacturing processes.

“We are delighted to open our new facility in Haimen, a project credited to the collaborative efforts of SIMM, Chinese Academy of Sciences and the Haimen government,” said Qun Shao, chief operations officer, Crystec. “This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China.”

The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology Ltd., and its UK headquarters in Bradford, UK, to expand and enhance product development services offered across the region and globally.